TerminatedPhase 1NCT01863004
Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin
Studying Dysferlin-related limb-girdle muscular dystrophy R2
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Basel, Switzerland
- Principal Investigator
- Michael Sinnreich, Prof. Dr. MDSponsor-Investigator, Neuromuscular Center, Neurology Clinic, University Hospital Basel, Switzerland
- Intervention
- Bortezomib(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2017
Study locations (1)
- Neuromuskuläres Zentrum, Universitätsspital Basel, Basel, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01863004 on ClinicalTrials.govOther trials for Dysferlin-related limb-girdle muscular dystrophy R2
Additional recruiting or active studies for the same condition.
See all trials for Dysferlin-related limb-girdle muscular dystrophy R2 →